Variability of Plasma Anti-Xa Activities with Different Lots of Enoxaparin

Annals of Pharmacotherapy

Volumn 38, Issue 4, 2004, Pages 563-568

  Gosselin, Robert C ^a   King, Jeffery H ^a,b   Janatpour, Kim A ^a   Dager, William E ^a   Larkin, Edward C ^a   Owings, John T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti Xa activity; Enoxaparin; Lot variability; Low molecular weight heparin

Indexed keywords

BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULATION; ARTICLE; CALIBRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; PLASMA; PRIORITY JOURNAL;

ANTICOAGULANTS; CALIBRATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENOXAPARIN; FACTOR XA; HUMANS; QUALITY CONTROL; REFERENCE STANDARDS; WORLD HEALTH ORGANIZATION;

EID: 1542639515     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D245     Document Type: Article

References (17)

1. Kitchen S, Theaker J, Preston FE. Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay. Blood Coagul Fibrinolysis 2000;11:137-44.
2. Kovacs MJ, Keeney M, MacKinnon K, Boyle E. Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin. Clin Lab Haematol 1999;21:55-60.
3. Kitchen S. Problems in laboratory monitoring of heparin dosage. Br J Haematol 2000;111:397-406.
4. Package insert. Lovenox (enoxaparin sodium injection). Bridgewater, NJ: Aventis Pharmaceuticals, July 2003.
5. Frantzen HG, Abildgaard U, Aasen AO. Simplified assay or antithrombin III activity using chromogenic peptide substrate. Manual and automated method. Scand J Haematol 1983;31:427-36.
6. Greaves M. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost 2002;87:163-4.
7. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:64S-94S.
8. Streif W, Mitchell LG, Andrew M. Antithrombotic therapy in children. Curr Opin Pediatr 1999;1:56-64.
9. Bowles L, Cohen H. Inherited thrombophilias and anticoagulation in pregnancy. Best Pract Res Clin Obstet Gynaecol 2003;17:471-89.
10. Samama MM, Poller L. Contemporary laboratory monitoring of low molecular weight heparins. Clin Lab Med 1995;15:119-23. Erratum: Clin Lab Med 1995;15:viii.
11. Samama MM, Poller L. Contemporary laboratory monitoring of low molecular weight heparins. Clin Lab Med 1995;15:119-23. Erratum: Clin Lab Med 1995;15:viii.
12. Hofmann S, Knoefler R, Lorenz N, Siegert G, Wendisch J, Mueller D, et al. Clinical experiences with low-molecular weight heparins in pediatric patients. Thromb Res 2001;103:345-53.
13. Ginsberg JS, Bates SM. Management of venous thromboembolism during pregnancy. J Thromb Haemost 2003;1:1435-42.
14. Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med 2002;162:2605-9.
15. Chow SL, Zammit K, West K, Dannenhoffer M, Lopez-Candales A. Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol 2003;43:586-90.
16. Brandt JT. CG2-A participant summary report. Northfield, IL: College of American Pathologists, 2000.
17. Laposata M, Green D, Van Cott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 1998;122:799-807.